feedback

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit
1.0 CNE Contact Hour
Released: May 10, 2019
Expires: May 10, 2020
1.0 hour to complete

Accredited By

This activity is jointly provided by Medical Education Resources and CMEology.

Media

Internet activity

Target Audience 

This certified activity is intended for nephrologists and other health care providers who have the opportunity to care for patients with ADPKD.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess the risk of rapid disease progression in patients with ADPKD
  • Apply strategies to individualize ADPKD management according to progression and treatment response

Activity Description

This activity will feature a patient at high risk for progression of autosomal dominant polycystic kidney disease (ADPKD) and chronicle her journey through diagnosis, assessment, treatment planning, and monitoring. It will address the role of the specialist and will include factors that influence progression of ADPKD, kidney size determined by MRI, estimating risk of progression, and disease-modifying therapy. Emphasis will be placed on the collaborative process, illustrating multidisciplinary approaches to the continuum of care.

Statement of Educational Need

ADPKD is the most common genetic renal disorder. ADPKD is associated with a diminished quality of life and high health care utilization and costs. The unmet needs associated with ADPKD are among the greatest of all renal diseases. Recent advances in the diagnosis and treatment of ADPKD offer opportunities for timely intervention and better outcomes in patients. However, ADPKD is often identified late, and care may not be effectively coordinated with specialists. Even in those diagnosed with ADPKD in a timely manner, health care providers may not adequately identify patients at risk for rapid ADPKD progression, knowledge that is important to the individualization of management. Ongoing management for ADPKD requires multidisciplinary care and coordination to assess progression, optimize care for renal and nonrenal manifestations, and identify patients appropriate for disease-modifying therapy. This activity is intended to enhance knowledge in the assessment of progression risk and ongoing management of ADPKD for nephrology specialists.

Goals (Purpose) of Program 

Health care providers who complete this activity should be able to recognize and assess the risk for disease progression in patients with ADPKD and enhance co-management and collaboration with the multidisciplinary team.

Faculty

York Pei, MSc, MD, FRCPC
York Pei, MSc, MD, FRCPC
Professor of Medicine
University of Toronto
Staff Nephrologist
Toronto General Hospital
University Health Network
Toronto, Canada

Conflict of Interest Policy/Disclosure Statement

It is the policy of Medical Education Resources (MER) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty has disclosed the following:

York Pei, MSc, MD, FRCPC
Consulting Fees: Otsuka, Sanofi, and Vertex

The following CMEology planners and managers, Beth Goodwin, Rob Lowney, and Dana Ravyn, PhD, MPH, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity of any amount during the past 12 months.

The following MER planner and manager, Julie Johnson, PharmD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity of any amount during the past 12 months.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians and nurses.

Credit Designation
Medical Education Resources designates this online activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.  

Continuing Nursing Education

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This CE activity provides 1.0 contact hour of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hour.

Instructions for Receiving Credit

A brief post-test and course evaluation will follow the completion of the course. Please complete these questionnaires to claim credit for this course.

Requirements for Successful Completion

Upon successfully completing the post-test with a score of 75% or better and the completion of the activity evaluation, the certificate will be made available immediately. 

Statement of Commercial Support

This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions about the Activity

For questions about the certification of this activity, please contact CMEology at: info@cmeology.org.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.